scholarly journals Sartans in the treatment of high-risk hypertension: the abilities of candesartan

2013 ◽  
Vol 10 (2) ◽  
pp. 13-18
Author(s):  
T E Morozova

This paper presents an overview of the literature on the treatment of arterial hypertension drugs that block the renin-angiotensin-aldosterone system (RAAS) – angiotensin receptor blockers ΙΙ (ARB), whose action is based on inhibition of the RAAS at the AII receptor. ARB candesartan (atakand), along with a strong long-term antihypertensive effect has organoprotective (causes regression of LVH has nephroprotection) antidiabetogennym effect, prevents the development of stroke. Clinical experience suggests candesartan, high efficiency and a good range of security among different categories of hypertensive patients with concomitant pathology, chronic heart failure, diabetes, obesity.

2014 ◽  
Vol 11 (3) ◽  
pp. 33-38
Author(s):  
T E Morozova ◽  
T B Andrushchishina ◽  
S V Gontarenko

The article presents an overview of the literature on the choice of pharmacotherapy of arterial hypertension (AH). Among antihypertensive drugs occupy an important place ARBs II (BRA), a heterogeneous group of drugs whose representatives have significant intercompany differences. This article focuses on the properties and effects of olmesartan, that distinguish it from other ARBs. Along with a strong long-term antihypertensive effect of olmesartan has organoprotective (regression of LVH, nephroprotection etc.). Olmesartan clinical experience indicates a high efficiency and a good range of security among different categories of patients with hypertension.


Sign in / Sign up

Export Citation Format

Share Document